The effect of ultrasonography guided intra-articular corticosteroid injections in advanced knee osteoarthritis

İleri evre diz osteoartritinde ultrasonografi eşliğinde intraartiküler uygulanan kortikosteroidlerin etkisi

Figen Koçyiğit*, Ersin Kuyucu**, Ali Koçyiğit***

* Pamukkale Üniversitesi, Fizik Tedavi ve Rehabilitasyon Yüksekokulu, Denizli
** Denizli Devlet Hastanesi, Ortopedi ve Travmatoloji Kliniği, Denizli
*** Pamukkale Üniversitesi Tıp Fakültesi, Radyoloji AD, Denizli

Abstract

Purpose: The aim of the study is to evaluate the effect of ultrasonography-guided intra-articular corticosteroid injection on pain, functional status and quality of life in patients with advanced knee osteoarthritis.

Materials and methods: 50 knees of 26 patients who were diagnosed as grade 4 knee osteoarthritis according to Kellgren - Lawrence classification system were treated with ultrasonography-guided intra-articular injection of 40 mg triamcinolone acetonide. Perceived pain, weekly analgesic consumption, findings of physical examination, knee pain threshold, functional status and quality of life were evaluated before and four weeks after the injection. Western - Ontario and McMaster Universities’ (WOMAC) osteoarthritis index was used to assess functional status, and Nottingham Health Profile (NHP) was used to evaluate the quality of life.

Results: Mean age of the patients in the study was 65±7.5 years and mean symptom duration was 74.7± 32.5 months. Visual analog scale for pain decreased from 85.3±14.1 mm to 59, 6±21.1 mm (p=0.003) and mean analgesic consumption decreased from 8±3 to 3±2 (p=0.000). Total WOMAC score (p=0.000) and scores of 4 NHP subdivisions (pain (p=0.000); physical mobility (p=0.003), social isolation (p=0.012); emotional reactions (p=0.016) decreased significantly 4 weeks after the injection.

Conclusion: Injection under ultrasonography guidance may improve the beneficial effects of corticosteroids in advanced knee osteoarthritis.


Key words: intraarticular injection, corticosteroids, osteoarthritis; interventional ultrasonography.

Özet

Amaç: Bu çalışmanın amacı ileri evre diz osteoartrit ile olan hastalarda, ultrasonografi eşliğinde yapılan intraartiküler kortikosteroid enjeksiyonlarının, ağrı, fonksiyonel durum ve hayat kalitesi üzerine olan etkilerini araştırmasıdır.

Gereç ve yöntem: Kellgren –Lawrence sınıflandırma sisteminine göre evre 4 diz osteoartrit olan hastanın 50 dizine ultrasonografi eşliğinde intraartiküler 40 mg triamcinolon acetonid uygulanması. Hastanın algıladığı ağrı, haftalık analjezik ilaç ihtiyacı, fizik muayene bulguları, fiziksel aktivite, sosyal izolasyon ve durumun değerlendirilmesi için Western - Ontario ve McMaster Üniversiteleri (WOMAC) osteoartrit indeksi, yaşam kalitesinin değerlendirilmesi için Nottingham Sağlık Profili (NHP) kullanıldı.

Bulgular: Çalışmaya dahil edilen hastaların ortalama yaş 65±7.5 yıl, belirtili süresi 74.7± 32.5 aydı. Ağrı için vücut analoj analog skala 85.3±14.1 mm den 59,6±21.1 mm’ye (p=0.003) haftalık analjezik tüketimi ise 8±3 tabletten 3±2 tablete (p=0.000) geriledi. Toplam WOMAC skorunun (p=0.000) ve NHP ağrı (p=0.000), fiziksel aktivite (p=0.003), sosyal izolasyon (p=0.012) ve emosyonel reaksiyonlar (p=0.016) skorları enjeksiyondan 4 hafta sonra istatistiksel olarak anlamlı şekilde azaldı.

Sonuç: İleri evre diz osteoartritinde enjeksiyonun ultrasonografi eşliğinde yapılması kortikosteroidlerin yararlarını arttırlabilir.

Pam Tip Derg 2015;8(3):193-198

Anahtar sözcükler: Intraartiküler enjeksiyonlar, kortikosteroidler, osteoartrit; girişimsel ultrasonografi.
Introduction

Knee osteoarthritis may affect functional capacity and quality of life as a result of pain, stiffness and decreased range of motion [1]. Pain management and continuation of daily life activities are important issues especially in patients with advanced knee osteoarthritis who are not suitable for surgery or do not accept surgical treatment.

Intra-articular (IA) corticosteroid injection is a treatment alternative for patients who do not respond to or cannot tolerate oral and parenteral systemic treatment [2]. American College of Rheumatology (ACR) reported IA corticosteroids as an appropriate treatment choice for patients who did not respond to preliminary treatment [3]. Knee pain is reported to decrease in the first 1-2 weeks after the injection in reviews evaluating the effects of IA corticosteroids in knee osteoarthritis. However, authors commented that the effect is not expected to last longer than 3-4 weeks [4, 5]. The targeting accuracy of IA injection is a critical factor for the duration of analgesic effect. Blinded IA injections without using a guide were reported to reach IA space in 64-87% of the administrations [6]. To the best of our knowledge, Ultrasonography (USG) guidance was not used in the previous studies about the effect of IA corticosteroid injection in advanced knee osteoarthritis.

The objective of our study is to evaluate the impact of USG guided IA corticosteroid injection on pain, quality of life, functional status and the analgesic need in patients with Kellgren-Lawrence grade 4 knee osteoarthritis.

Materials and Methods

Patients and Clinical Evaluation

Our study included 50 knees of 26 patients who were diagnosed as knee osteoarthritis according to ACR clinical and radiological diagnostic criteria and had grade 4 according to Kellgren-Lawrence radiological classification.

The exclusion criteria were presence of knee effusion, presence of inflammatory joint disease, history of IA knee injection in last 6 months and presence of contraindication for corticosteroid use. Two patients had total knee arthroplasty in one lower extremity and these two knees were not involved in the study. We questioned and recorded the demographic parameters, symptom duration, comorbidities, pain severity on 100 mm visual analog scale, analgesic need for one week of the recruited patients. We measured active range of motion of the knee. We evaluated the presence of knee joint medial and lateral tenderness, and inflammatory findings. We measured pain threshold at medial joint space with pressure algometer (Wagner Pain Test™ Model FPK 40 Algometer, Wagner Instruments, Greenwich, CT, USA). We applied Western –Ontario and McMaster Universities’ (WOMAC) osteoarthritis index and Nottingham Health Profile (NHP) to evaluate functional status and quality of life.

WOMAC osteoarthritis index was developed in 1982 to assess pain, stiffness, and physical function in patients with hip and / or knee osteoarthritis. It is divided in three subscales (pain, stiffness, and physical function) and consists of 24 items evaluated by Likert scale. Validity and reliability of the Turkish version was documented in 2005 [7].

NHP is a self administered questionnaire that is used to determine and quantify perceived health problems. It is divided in 6 subscales (sleep, mobility, energy, pain, emotional reactions, social isolation) and consists of 38 items [8]. Validity and reliability of the Turkish version was documented in 2000 [9].

All of the participants gave written and oral informed consent. Patients were advised to use their analgesic when they experience pain that did not resolve with rest. The analgesic preferred by the patient was paracetamol in 16 patients, diclofenac sodium in 4 patients, ibuprofen in 4 patients and naproxen in 2 patients. We gave an analgesic diary to participants and requested to record their analgesic consumption. We did not change exercise receipt of the patients who do regular training. New exercise schedule was not given to patients who do not do regular exercise. We invited the patients to follow-up visits four weeks after the injection, and clinical and functional evaluations were repeated. Clinical evaluations of the patients were applied by the same investigator. Probable side effects of corticosteroid use such as injection site depigmentation, local atrophy, increase in blood pressure and blood glucose levels were questioned and assessed.

USG guided knee injection

An experienced invasive radiologist (AK) injected 40 mg triamcinolone acetonide (TA) intra-artistically via medial approach under USG (Aplo XG, Toshiba Medicals, Tokyo, Japan) guidance after the clinical evaluation. Patient was laid in the supine position with the knee in full extension during the procedure. The
7.5-12 MHz linear array probe was prepared and clothed according to standard sterility conditions. Probe was placed slightly oblique to medial patellar margin and 38 mm 22 gauge needle was placed 45 degrees obliquely to the long axis of USG probe (Figure 1). Needle was inserted towards patellofemoral recess to reach intra-articular space (Figure 2). When needle tip is visualized in the IA space, a test injection of TA (0.1 ml) was performed to check that the tip of the needle is in the correct position. When the injected fluid is seen in the articular space as hyperechoic bubbles, the rest of TA was infused slowly into the IA space (Figure 3). The radiologist terminated the procedure after the diffusion of drug in the articular space was observed on USG. The radiologist paid attention in order not to harm patellar and femoral cartilage during the procedure.

Figure 1. The probe and needle position for medial approach. The 45° angle between the probe and needle is also showed on the figure.

Figure 2. Demonstration of the sonographic image in medial approach. P; patella, PFR; patellofemoral recess, F; femur and the line marked with stars is articular space.

Figure 3. The air bubbles can be seen in the articular space after injection (White arrows). P; patella, F; femur.

Statistical Analysis

Statistical analysis was performed with SPSS software, release 17.0 (SPSS Inc., an IBM Company, and Chicago, IL, USA). Standard descriptive statistics were used to summarize characteristics of the participants including means and standard deviations (SD) of all continuous variables and counts and percentages for the categorical variables. A-paired-sample T-test was used to compare objective outcomes. We defined two-sided statistical significance as \( p<0.05 \).

Results

The study included 50 involved knees of 26 patients (4 male, 22 female). Mean age of the participants was 65 ± 7.5 years (range, 57-79 years), and mean symptom duration was 74.7 ± 32.5 months (range, 12-120 months). When we analyzed comorbidities of the patients; hypertension, and gastroesophageal reflux were present in 8 patients, diabetes mellitus and hyperlipidemia were present in 6 patients. Major depression, hypothyroidism, coronary heart disease were present in 4 patients (one patient may have more than 1 comorbidities). Three of the patients did not have any comorbidities.

The mean number of weekly consumed analgesics was 8 ± 3 tablets (range, 3-14 tablets). Knee joint medial tenderness was present in all of the 50 knees whereas knee joint; lateral tenderness was present in 42 of 50 knees. Mean pain pressure threshold was 5.11 ± 1.1 kg (3-7.5 kg). Mean knee flexion was 120 ± 10.7° (range, 95-135°), mean knee extension was 5.2 ± 5.9° (range, 0-15°).

Mean VAS for pain before the injection was 85.3 ± 14.1 mm (range, 47-98 mm). Mean total
WOMAC score was 76 ± 14 (range, 52-96). Mean NHP pain score was 94 ± 9 (range, 75-100), mean NHP physical activity score was 94 ± 9 (range, 75-100). Patients applied for follow-up 33±8 days (range, 24-51 days) after the injection.

Weekly analgesic consumption decreased to 3±2 and mean VAS for pain decreased to 59.6 ± 21.1 mm. These changes in VAS for pain (p=0.003) and the analgesic need (p=0.000) after IA TA injection was significant statistically.

Regarding the physical examination findings there was no significant difference in the knee joint medial tenderness after the injection. However, lateral joint space tenderness was present in 26 of 50 patients, and this change was significant statistically (p=0.039). Pressure pain threshold increased 4 weeks after the injection, but this change was not significant (Table 1).

Table 1. Changes in VAS pain threshold, analgesic consumption and physical examination findings after the treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>4th-week follow-up</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of analgesic pill/week</td>
<td>8 ± 3</td>
<td>3 ± 3</td>
<td>0.000</td>
</tr>
<tr>
<td>VAS*, for pain (mm)</td>
<td>85.3±14.1 (47-98)</td>
<td>59.7 ± 21.1 (22-97)</td>
<td>0.003</td>
</tr>
<tr>
<td>Pain threshold (kg)</td>
<td>5.1 ± 1.1 (3-7.5)</td>
<td>5.8 ± 2.5 (2.5-12)</td>
<td>0.51</td>
</tr>
<tr>
<td>Knee joint lateral tenderness**</td>
<td>42/50</td>
<td>26/50</td>
<td>0.039</td>
</tr>
<tr>
<td>Knee joint medial tenderness**</td>
<td>50/50</td>
<td>46/50</td>
<td>0.34</td>
</tr>
<tr>
<td>Knee flexion</td>
<td>120 ± 10.7°(95-135°)</td>
<td>120 ± 10.5°(100-135°)</td>
<td>0.58</td>
</tr>
<tr>
<td>Knee extension</td>
<td>5.2 ± 5.9° (0-15°)</td>
<td>5.6 ± 5.9° (0-15°)</td>
<td>0.54</td>
</tr>
</tbody>
</table>

*: Visual analog scale
**: Demonstrated as number of knees with tenderness/total number of knees

Table 2. Changes in total WOMAC score and WOMAC subdivision scores after the treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>4th-week follow-up</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WOMAC* pain score</td>
<td>15.9 ± 3.6</td>
<td>10.3 ± 4.1</td>
<td>0.002</td>
</tr>
<tr>
<td>WOMAC stiffness score</td>
<td>5.8 ± 2</td>
<td>2.5 ± 2.1</td>
<td>0.006</td>
</tr>
<tr>
<td>WOMAC physical function score</td>
<td>55.2 ± 10.7</td>
<td>33.4 ± 11.3</td>
<td>0.000</td>
</tr>
<tr>
<td>WOMAC total score</td>
<td>76.8 ± 14.2</td>
<td>46.2 ± 15.1</td>
<td>0.000</td>
</tr>
<tr>
<td>Total</td>
<td>26</td>
<td>26</td>
<td></td>
</tr>
</tbody>
</table>

*: Western-Ontario and McMaster Universities’ osteoarthritis index

Table 3. NHP subdivision scores before and 4 weeks after the treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>4th-week follow-up</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHP* pain</td>
<td>94.2 ± 9.7</td>
<td>57.1 ± 20</td>
<td>0.000</td>
</tr>
<tr>
<td>NHP physical mobility</td>
<td>70.2 ± 19.5</td>
<td>47.1 ± 17.1</td>
<td>0.003</td>
</tr>
<tr>
<td>NHP energy</td>
<td>66.6 ± 30.5</td>
<td>61.5 ± 42.7</td>
<td>0.587</td>
</tr>
<tr>
<td>NHP sleep</td>
<td>58.5 ± 33.1</td>
<td>41.5 ± 38.7</td>
<td>0.127</td>
</tr>
<tr>
<td>NHP social isolation</td>
<td>25 ± 23.3</td>
<td>7.7 ± 10.1</td>
<td>0.012</td>
</tr>
<tr>
<td>NHP emotional reactions</td>
<td>38.6 ± 31.9</td>
<td>15.4 ± 20.5</td>
<td>0.016</td>
</tr>
<tr>
<td>Total</td>
<td>26</td>
<td>26</td>
<td></td>
</tr>
</tbody>
</table>

*: Nottingham Health Profile
Discussion

We investigated the effect of 40 mg IA TA applied under USG guidance on pain, physical examination findings, analgesic consumption, functional status and quality of life in patients with advanced knee osteoarthritis in this study. Intra-articular TA improved pain, the analgesic need, physical activity and life quality of patients significantly after 4 weeks.

The effect of IA corticosteroids in knee osteoarthritis was documented in previous studies. However, duration of the effect is a matter of debate. Recent reviews reported a 1-2 week length of corticosteroid effect and predicted effect duration to be not more than 1-2 weeks [4, 5]. USG guided IA injection was shown to be effective after 4 weeks of this study in advanced knee osteoarthritis.

Probability of IA injections’ reaching IA space is not 100% even when applied to the large and superficial joints by experienced rheumatologists. The probability decreases especially in obese patients with ‘dry’ knees without effusion [10]. The aim of IA injections is to provide high concentrations of corticosteroid in the synovial fluid, to reduce local inflammation while minimizing plasma concentrations and systemic side effects [11]. Therefore, these injections may be performed under fluoroscopy, direct roentgenogram and USG guidance.

Gaffney et al. [12] conducted a study to compare 20 mg IA triamcinolone hexacetonide with placebo in knee osteoarthritis and reported significant improvement in pain with triamcinolone at the end of the first week. However, there was no difference between the groups at the end of 6 weeks. Dieppe et al. [13] conducted a similar study in 12 patients with symptom duration of 7.5 years. They compared 20 mg IA triamcinolone hexacetonide with placebo and reported significant difference of VAS for pain only at the first week. Ravaud et al. [14] reported a 4-week duration of the effect of IA cortivazol when compared to joint lavage. VAS for pain, and subdivisions of both NHP and WOMAC scores for pain decreased significantly in our study. Furthermore, analgesic consumption decreased significantly. The number of weekly consumed analgesic pills decreased to 3±2 from 8±2. This decline in analgesic consumption is striking and significant when the geriatric nature and high number of comorbidities in our patient group are taken into account. The decrease in pain severity despite decrease in analgesic consumption is also significant. USG guidance was not used in any of the previous studies evaluating the effect of IA corticosteroids in knee osteoarthritis [4, 5]. Moreover, the applied dose was smaller than the ACR recommended dose [12-14]. Application of the recommended dose under USG guidance may have ameliorated the analgesic effect in this study even the patient group had advanced osteoarthritis.

The objective of treatment in advanced knee osteoarthritis is pain relief and independence in activities of daily living. Change in range of motion with treatment is not expected. We also did not observe difference in range of motion and knee joint medial tenderness. However, number of knees with knee joint, lateral tenderness decreased significantly in 4 weeks. Knee osteoarthritis affects the medial compartment more prominently. Despite being high grade according to radiological evaluation, the anti-inflammatory effect of TA may have alleviated the tenderness in lateral knee compartment. Widespread peri-articular tenderness in the knee makes lateral decubitus position difficult for the patient. Nevertheless, tenderness only in the medial joint space allows lateral decubitus position with a pillow between knees if necessary. Previous studies on IA corticosteroids for knee osteoarthritis did not evaluate the effect on joint tenderness. We believe that this is the first survey that allows to comment on joint tenderness after IA TA. We also observed increase in pain pressure threshold which supports analgesic effect of the IA TA. However, the change was not significant statistically.

The decrease in score of energy, sleep, pain, emotional reactions, social isolation, and physical mobility subdivisions of NHP implies an increase in the perceived quality of life. Both the total score and score of subdivisions of WOMAC osteoarthritis index decreased significantly. Jones and Doherty [15] reported no difference in quality of life assessed with Stanford Health Assessment Questionnaire (HAQ) at weeks 3 and 8 in patients having knee osteoarthritis and treated with IA 40 mg methylprednisolone. Ravaud [14] reported significant improvement in functional status evaluated by Lequesne index at weeks 1 and 4 but not beyond. Furthermore, they reported a better functional status in IA lavage group compared to IA cortivazol. Gaffney et al. [12] showed significant improvement in health status assessed by HAQ at weeks 1 and 6 compared to placebo. Despite these contradictory results, a recent Cochrane Database review declared lack of evidence
concerning the effect of corticosteroids on functional parameters [16]. This study demonstrated significant improvement in parameters related to both quality of life and functional status. Our results represented progress in functional status together with pain relief and improved emotional status and social isolation in parallel.

Our study had several limitations. First, our study group is relatively small and, therefore, our results need to be validated by further studies with larger series including early stages of knee osteoarthritis. Secondly, a blinded IA injection control group is absent in our study. However blinded IA corticosteroid injection in osteoarthritis is an extensively studied technique in literature. Therefore, we did not compose a blinded injection control group. On the other hand, addition of the control group would provide a comparison of guided and blinded injection techniques. Thirdly our follow-up duration is 4 weeks. Further studies with longer follow-up are needed to document long-term effect of USG guided knee injections.

In conclusion, our study demonstrated a significant analgesic effect of USG guided IA injection at 4 weeks of follow-up. In addition, significant improvement in physical examination findings, functional status and quality of life was obtained. USG guidance may improve the known beneficial effects of corticosteroids in advanced knee osteoarthritis.

Conflict of interest: Authors declare that they have no conflict of interest.

References